Have a feature idea you'd love to see implemented?
Let us know!
DNTH Dianthus Therapeutics Inc
Price (delayed)
$20.27
Market cap
$599.93M
P/E Ratio
2.83
Dividend/share
N/A
EPS
$7.16
Enterprise value
$566.57M
magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused
Highlights
The EPS has soared by 120% YoY and by 74% QoQ
DNTH's debt has dropped by 54% year-on-year and by 24% since the previous quarter
DNTH's equity has soared by 89% YoY but it is down by 6% QoQ
Dianthus Therapeutics's quick ratio has decreased by 50% QoQ but it has increased by 24% YoY
Dianthus Therapeutics's net income has shrunk by 56% YoY and by 18% QoQ
Key stats
What are the main financial stats of DNTH
Market
Valuations
Earnings
Shares outstanding
29.6M
Market cap
$599.93M
Enterprise value
$566.57M
Price to book (P/B)
1.76
Price to sales (P/S)
129.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.59
Revenue
$5.37M
EBIT
-$67.09M
EBITDA
-$66.66M
Free cash flow
-$62.67M
Per share
Balance sheet
Liquidity
EPS
$7.16
Free cash flow per share
-$1.83
Book value per share
$11.51
Revenue per share
$0.16
TBVPS
$10.35
Total assets
$354.25M
Total liabilities
$16.35M
Debt
$311,000
Equity
$337.9M
Working capital
$271.78M
Debt to equity
0
Current ratio
18.3
Quick ratio
18.07
Net debt/EBITDA
0.5
Margins
Efficiency
Dividend
EBITDA margin
-1,242.2%
Gross margin
100%
Net margin
-1,250.3%
Operating margin
-1,545%
Return on assets
-20.9%
Return on equity
-21.7%
Return on invested capital
-62%
Return on capital employed
-19.8%
Return on sales
-1,250.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNTH stock price
How has the Dianthus Therapeutics stock price performed over time
Intraday
-2.41%
1 week
-20.48%
1 month
-28.58%
1 year
76.26%
YTD
94.9%
QTD
-25.97%
Financial performance
How have Dianthus Therapeutics's revenue and profit performed over time
Revenue
$5.37M
Gross profit
$5.37M
Operating income
-$82.9M
Net income
-$67.09M
Gross margin
100%
Net margin
-1,250.3%
The operating income has plunged by 81% YoY and by 21% from the previous quarter
Dianthus Therapeutics's net income has shrunk by 56% YoY and by 18% QoQ
The gross profit has surged by 51% year-on-year and by 30% since the previous quarter
The revenue has soared by 51% YoY and by 30% from the previous quarter
Growth
What is Dianthus Therapeutics's growth rate over time
Valuation
What is Dianthus Therapeutics stock price valuation
P/E
2.83
P/B
1.76
P/S
129.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
105.59
The EPS has soared by 120% YoY and by 74% QoQ
DNTH's equity has soared by 89% YoY but it is down by 6% QoQ
The stock's price to book (P/B) is 7% less than its last 4 quarters average of 1.9 and 2.2% less than its 5-year quarterly average of 1.8
The revenue has soared by 51% YoY and by 30% from the previous quarter
DNTH's P/S is 20% below its last 4 quarters average of 161.9
Efficiency
How efficient is Dianthus Therapeutics business performance
The ROE has soared by 64% YoY but it has decreased by 3.3% QoQ
DNTH's return on invested capital has surged by 59% since the previous quarter and by 56% year-on-year
DNTH's return on assets is up by 47% year-on-year but it is down by 3.5% since the previous quarter
The ROS rose by 9% QoQ but it fell by 2.8% YoY
Dividends
What is DNTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNTH.
Financial health
How did Dianthus Therapeutics financials performed over time
DNTH's total assets has soared by 84% YoY but it is down by 4% QoQ
The company's total liabilities has surged by 52% QoQ and by 16% YoY
DNTH's debt is 100% smaller than its equity
DNTH's equity has soared by 89% YoY but it is down by 6% QoQ
DNTH's debt has dropped by 54% year-on-year and by 24% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.